Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies

  • End date
    Jan 31, 2023
  • participants needed
  • sponsor
    Novartis Pharmaceuticals
Updated on 24 May 2021


This is a multicenter, uncontrolled, open-label, special drug use study to investigate the safety and efficacy of Xolair by collecting data in its clinical setting in patients with severe to most severe seasonal allergic rhinitis aged 12 years and < 18 years whose symptoms were inadequately controlled despite to conventional therapies and used Xolair.


The observation period will last for up to 24 weeks, with Day 1 defined as the start date of Xolair treatment. It should be noted that, because the duration of Xolair treatment depends on the pollen dispersal situation and other factors, patients who complete or discontinue Xolair treatment before the visit at 24 weeks after the start of treatment will be followed up until the date of last dose of Xolair + 30 days, and the results will be recorded in the CRF.

Condition Allergic Rhinitis
Treatment Xolair
Clinical Study IdentifierNCT04648930
SponsorNovartis Pharmaceuticals
Last Modified on24 May 2021


Yes No Not Sure

Inclusion Criteria

Patients who used Xolair in accordance with the instructions of package insert
Patients aged 12 years and < 18 years at the start of Xolair
Patients who used Xolair for the following indication
Indication: seasonal allergic rhinitis (only patients with severe to most
severe symptoms whose symptoms were inadequately controlled despite to
conventional therapies) 4. Patients having provided written consent to
participate in this study before the start of Xolair in the relevant pollen
season, in person and from their legally acceptable representative (legal

Exclusion Criteria

Patients with a history of hypersensitivity to any of the Xolair ingredients
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note